Revolutionising Communication: Neuroprosthetic System Transforms Neural Activity into Speech for Paralyzed Individuals

By Michael Awood

August 30, 2023

In a pioneering study, researchers have created a multimodal speech neuroprosthetic system that could potentially restore full communication to those with severe paralysis. This innovative system decodes and converts neural activity into text, speech audio, and facial-avatar animation using high-density surface recordings of the speech cortex.

The system’s capabilities were demonstrated by a 47-year-old woman with severe limb and vocal paralysis caused by a basilar artery brainstem stroke. Despite her inability to vocalize or type, she achieved a median rate of 78 words per minute with a 25% word error rate using the neuroprosthetic system, significantly surpassing her previous rate of 14 words per minute using a commercial head-tracking system. The researchers even synthesized speech audio in her pre-injury voice and created a personalized avatar capable of realistic and interpretable speech and non-verbal facial gestures.

The neuroprosthetic system showed high performance within two weeks of training, outperforming previous brain-computer interfaces by four times in communication speed and twenty times in vocabulary size.

The study recognizes the need for further validation in other individuals with varying types of paralysis, as it is a proof-of-concept study based on a single patient. Future developments in electrode interfaces and real-time closed-loop feedback during decoding could improve user engagement, model performance, and neural entrainment.

This breakthrough offers immense potential for those living with paralysis. Improved communication through evolving technology could significantly enhance their quality of life by enabling meaningful interpersonal interactions.

The study participant expressed how this technology could enhance her daily life by improving expressivity, independence, and productivity. The ultimate goal is to integrate this technology seamlessly into real-world applications, offering hope to those living with speech loss due to severe paralysis.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.